Subcutaneous Contraceptive and HIV Implant Engineered for Long-Acting Delivery (SCHIELD) in Multipurpose Prevention Technology (MPT)
The study proposes to develop and test an innovative multipurpose prevention technology (MPT) in the form of a Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Delivery (SCHIELD).
The proposed innovative implant will offer a combination of attributes that surpass existing PrEP delivery systems: user-independence, biodegradation, long-term protection (up to 1 year), and discretion of use.
The study has three Specific Aims:
- to develop a long acting MPT implant in the form of a subcutaneously inserted and biodegradable device that promotes adherence, acceptability, usage, and effectiveness over existing ARV and contraceptive delivery systems;
- to test the safety and pharmacokinetics of the SCHIELD device to deliver ARV drugs and contraceptive hormones by completion of exploratory and IND-enabling preclinical studies; and
Funding Agent: USAID through RTI International Grant #: APS-OAA-16-000002
Collaborators and Partners: RTI International, PATH, UNC, UCSF, Gilead Sciences, University of Pittsburgh, Setshaba Research Centre and IRDO
Study Site(s): TBD (likely Kisumu)